organization · Reporting owner

MVA Investors, LLC

Disclosed activity across 8 companies

Tapewire entity: 89263
SEC CIK: 0001468223

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Mirati Therapeutics, Inc.MRTX · Entity 94908	See remarks	January 23, 2024	January 25, 2024
Rain Oncology Inc.RAIN · Entity 94695	Director · 10% owner	April 23, 2021	April 27, 2021
Solid Biosciences Inc.SLDB · Entity 4915	10% owner	March 04, 2019	March 06, 2019
Tango Therapeutics, Inc.TNGX · Entity 1497	See remarks	June 28, 2024	July 03, 2024
Tyra Biosciences, Inc.TYRA · Entity 4680	See Remarks	February 06, 2024	February 08, 2024
iTeos Therapeutics, Inc.ITOS · Entity 75965	10% owner	January 03, 2022	January 05, 2022

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Mirati Therapeutics, Inc.

Report date January 23, 2024 · Filed January 25, 2024

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, Davis Aaron I., Dissanayake Shehan Bharatha, Fuglesang Christopher, Braslyn Ltd., Lockend Five, LLC

Security / award	Ownership account	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2024-01-23 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-01-23 · Disposition to issuer · Disposed 287,866 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2024-01-23 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2024-01-23 · Disposition to issuer · Disposed 203,754 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F4: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2024-01-23 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2024-01-23 · Disposition to issuer · Disposed 3,135,966 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.
Common StockSEC Table I · non-derivative	IndirectSee Footnote	Reported balance After 2024-01-23 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2024-01-23 · Disposition to issuer · Disposed 30,518 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F6: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities.
Common StockSEC Table I · non-derivative	Direct	Reported balance After 2024-01-23 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2024-01-23 · Disposition to issuer · Disposed 3,201,440 · Balance 0 F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration"). F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	Reported balance After 2024-01-23 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2024-01-23 · Disposition to issuer · Disposed 332,809 · Balance 0 F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee Footnote	Reported balance After 2024-01-23 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2024-01-23 · Disposition to issuer · Disposed 3,578,036 · Balance 0 F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.
Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	IndirectSee Footnote	Reported balance After 2024-01-23 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2024-01-23 · Disposition to issuer · Disposed 1,413,475 · Balance 0 F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein. F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock. F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

Filing footnotes · ownership attribution and instrument terms

F1: On January 23, 2024, Mirati Therapeutics, Inc. (the "Company") filed a Form 8-K with the SEC announcing the consummation of a transaction in which the Company became a wholly owned subsidiary of Bristol-Myers Squibb Company, as described in greater detail therein (the "Merger"). As described in that 8-K, upon the effective time (the "Effective Time") of the Merger each share of Company common stock, par value $0.001 per share, of the Company ("Common Stock") (with certain exceptions) was automatically converted into the right to receive (i) cash in an amount equal to $58.00 subject to applicable withholding tax and (ii) one contingent value right (a "CVR") representing the right to receive $12.00 in cash, without interest and subject to any applicable tax withholding upon achievement of a specified milestone is achieved (as further explained in the Form 8-K) (the consideration contemplated by (i) and (ii), together, the "Merger Consideration").

F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

F3: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Each of Messrs. Fuglesang, Dissanayake and Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

F4: These securities are owned directly by Lockend Five, LLC, a limited liability company owned soley by Mr. Dissanayake. Each reporting person other than Lockend Five, LLC and Mr. Dissanayake disclaims beneficial ownership of these securities.

F5: These securities are owned directly by Braslyn Ltd., which is owned by a revocable trust established by Mr. Lewis for the benefit of members of his immediate family. Each reporting person other than Braslyn Ltd. and Mr. Lewis disclaims beneficial ownership of these securities.

F6: These securities are owned directly by Mr. Fuglesang. Each reporting person other than Mr. Fuglesang disclaims beneficial ownership of these securities.

F7: By virtue of the Merger, each then unexpired and unexercised issued and outstanding warrant to purchase shares of Common Stock issued by or on behalf of the Company (each, a "Company Warrant") that was outstanding as of immediately prior to the Effective Time was converted into the right to receive, upon exercise of such Company Warrant, the same Merger Consideration as the holder would have been entitled to receive following the Effective Time if such holder had been, immediately prior to the Effective Time, the holder of the number of shares of Company common stock then issuable upon exercise in full of such Company Warrant without regard to any limitations on exercise contained therein.

F8: These Company Warrants do not have an expiration date and are not exercisable to the extent that, following exercise, the holder of such Company Warrant and its affiliates would beneficially own more than 19.99% of the Common Stock.

Rain Oncology Inc.

Report date April 23, 2021 · Filed April 27, 2021

Jointly reported with Davis Aaron I.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	1,175,000	Last balance in matching sequence After 2021-04-27 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2021-04-23 · Purchase · Acquired 25,000 · Balance 25,000 F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Row 2 · 2021-04-23 · Purchase · Acquired 125,000 · Balance 150,000 F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Row 3 · 2021-04-27 · Purchase · Acquired 1,025,000 · Balance 1,175,000 F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee Footnote	0	Reported balance After 2021-04-27 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-04-27 · Conversion · Disposed 3,263,986 · Balance 0 F2: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-04-27 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-04-27 · Conversion · Disposed 86,097 · Balance 0 F2: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F3: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, and indirectly by Mr. Davis who is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Non-Voting Common StockSEC Table II · derivative / convertible security	IndirectSee Footnote	3,022,489	Reported balance After 2021-04-27 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2021-04-27 · Conversion · Acquired 3,022,489 · Balance 3,022,489 F2: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Non-Voting Common StockSEC Table II · derivative / convertible security	Direct	79,726	Reported balance After 2021-04-27 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-04-27 · Conversion · Acquired 79,726 · Balance 79,726 F2: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F3: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, and indirectly by Mr. Davis who is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

F2: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer.

F3: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, and indirectly by Mr. Davis who is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Solid Biosciences Inc.

Report date March 04, 2019 · Filed March 06, 2019

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., Braslyn Ltd., LEWIS JOSEPH

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,923,272	Reported balance Holding disclosure · report date 2019-03-04 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 3,923,272 F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis and (v) MVA Investors, LLC ("MVA Investors") (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	11,488	Reported balance Holding disclosure · report date 2019-03-04 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 11,488 F2: These securities are owned directly by Braslyn and indirectly by Joseph C. Lewis, who is the sole indirect owner of and controls Braslyn. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	30,210	Reported balance Holding disclosure · report date 2019-03-04 · row 3 Holding and transaction disclosures are not merged. 1 source row Row 3 · Balance 30,210 F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis and (v) MVA Investors, LLC ("MVA Investors") (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

F2: These securities are owned directly by Braslyn and indirectly by Joseph C. Lewis, who is the sole indirect owner of and controls Braslyn. Each member of the Boxer Group other than Braslyn disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Tango Therapeutics, Inc.

Report date June 28, 2024 · Filed July 03, 2024

Jointly reported with Davis Aaron I.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	108,793	Last balance in matching sequence After 2024-07-02 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2024-06-28 · Sale · Disposed 29,000 · Balance 314,524 F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.48 to $8.68, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Row 2 · 2024-07-01 · Sale · Disposed 110,731 · Balance 203,793 F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.75 to $9.00, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any. Row 3 · 2024-07-02 · Sale · Disposed 95,000 · Balance 108,793 F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $9.05, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. F2: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.48 to $8.68, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F3: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.75 to $9.00, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.30 to $9.05, inclusive. The reporting person undertakes to provide the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote.

Tyra Biosciences, Inc.

Report date February 06, 2024 · Filed February 08, 2024

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, Davis Aaron I.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee Footnote	85,939	Reported balance After 2024-02-06 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-02-06 · Grant · Acquired 63,412 · Balance 85,939 F1: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
Warrant (right to purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $0.00	Direct	705,280	Reported balance After 2024-02-06 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2024-02-06 · Grant · Acquired 705,280 · Balance 705,280 F3: These Warrants are exercisable immediately (subject to any applicable beneficial ownership limitation) and do not have an expiration date. F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.
Common StockSEC Table I · non-derivative	Direct	6,448,359	Reported balance Holding disclosure · report date 2024-02-06 · row 2 Holding and transaction disclosures are not merged. 1 source row Row 2 · Balance 6,448,359 F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by MVA Investors, LLC ("MVA Investors"). Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each reporting person other than MVA Investors disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"). Boxer Asset Management Inc. ("Boxer Management") is the managing member of Boxer Capital. Joseph Lewis is the sole indirect owner of Boxer Management. Mr. Davis is a member of Boxer Capital. Each reporting person other than Boxer Capital disclaims beneficial ownership of these securities except to the extent of such person's pecuniary interest therein, if any.

F3: These Warrants are exercisable immediately (subject to any applicable beneficial ownership limitation) and do not have an expiration date.

iTeos Therapeutics, Inc.

Report date January 03, 2022 · Filed January 05, 2022

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, Davis Aaron I.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,912,113	Reported balance After 2022-01-03 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2022-01-03 · Sale · Disposed 432,903 · Balance 3,912,113 F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $47.4904 to $47.8617. F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	3,872,632	Reported balance After 2022-01-03 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2022-01-03 · Sale · Disposed 39,481 · Balance 3,872,632 F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $49.2035 to $50.1716. F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	3,855,459	Reported balance After 2022-01-03 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2022-01-03 · Sale · Disposed 17,173 · Balance 3,855,459 F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	48,890	Reported balance After 2022-01-03 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2022-01-03 · Sale · Disposed 23,353 · Balance 48,890 F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $47.4904 to $47.8617. F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group
Common StockSEC Table I · non-derivative	Direct	47,208	Reported balance After 2022-01-03 transaction · row 5 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 5 · 2022-01-03 · Sale · Disposed 1,682 · Balance 47,208 F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $49.2035 to $50.1716. F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group
Common StockSEC Table I · non-derivative	Direct	46,477	Reported balance After 2022-01-03 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2022-01-03 · Sale · Disposed 731 · Balance 46,477 F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group
Common StockSEC Table I · non-derivative	Direct	3,767,405	Reported balance After 2022-01-04 transaction · row 7 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 7 · 2022-01-04 · Sale · Disposed 88,054 · Balance 3,767,405 F5: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $41.4811 to $42.1440. F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	3,758,039	Reported balance After 2022-01-04 transaction · row 8 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 8 · 2022-01-04 · Sale · Disposed 9,366 · Balance 3,758,039 F6: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $42.6291 to $43.4221. F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	3,724,742	Reported balance After 2022-01-04 transaction · row 9 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 9 · 2022-01-04 · Sale · Disposed 33,297 · Balance 3,724,742 F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	3,717,259	Reported balance After 2022-01-04 transaction · row 10 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 10 · 2022-01-04 · Sale · Disposed 7,483 · Balance 3,717,259 F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Common StockSEC Table I · non-derivative	Direct	16,854	Reported balance After 2022-01-04 transaction · row 11 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 11 · 2022-01-04 · Sale · Disposed 29,623 · Balance 16,854 F5: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $41.4811 to $42.1440. F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group
Common StockSEC Table I · non-derivative	Direct	13,716	Reported balance After 2022-01-04 transaction · row 12 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 12 · 2022-01-04 · Sale · Disposed 3,138 · Balance 13,716 F6: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $42.6291 to $43.4221. F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group
Common StockSEC Table I · non-derivative	Direct	2,517	Reported balance After 2022-01-04 transaction · row 13 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 13 · 2022-01-04 · Sale · Disposed 11,199 · Balance 2,517 F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2022-01-04 transaction · row 14 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 14 · 2022-01-04 · Sale · Disposed 2,517 · Balance 0 F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group

Filing footnotes · ownership attribution and instrument terms

F1: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

F2: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Following the completion of the transactions reported in this Form 4, MVA Investors no longer holds any securities of the issuer and, therefore, as of January 4, 2022, is no longer a member of the Boxer Group

F3: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $47.4904 to $47.8617.

F4: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $49.2035 to $50.1716.

F5: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $41.4811 to $42.1440.

F6: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $42.6291 to $43.4221.

Past disclosures · reporting ended (2)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

PMV Pharmaceuticals, Inc.

Report date September 25, 2020 · Filed September 29, 2020

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., LEWIS JOSEPH, Davis Aaron I.

Section 16 reporting ended · disclosed 2020-09-29. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,268,236	Last balance in matching sequence After 2020-09-29 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 3 source rows Row 1 · 2020-09-25 · Purchase · Acquired 950,000 · Balance 950,000 F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. Row 2 · 2020-09-29 · Conversion · Acquired 586,099 · Balance 1,536,099 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. Row 3 · 2020-09-29 · Conversion · Acquired 732,137 · Balance 2,268,236 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	60,837	Last balance in matching sequence After 2020-09-29 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 4 · 2020-09-29 · Conversion · Acquired 32,708 · Balance 32,708 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Row 5 · 2020-09-29 · Conversion · Acquired 28,129 · Balance 60,837 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-09-29 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2020-09-29 · Conversion · Disposed 586,099 · Balance 0 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.
Series C Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-29 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2020-09-29 · Conversion · Disposed 32,708 · Balance 0 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Series D Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-09-29 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2020-09-29 · Conversion · Disposed 732,137 · Balance 0 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.
Series D Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-09-29 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2020-09-29 · Conversion · Disposed 28,129 · Balance 0 F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein.

F2: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date.

F3: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Pandion Therapeutics, Inc.

Report date July 21, 2020 · Filed July 21, 2020

Jointly reported with Boxer Capital, LLC, Boxer Asset Management Inc., Braslyn Ltd., LEWIS JOSEPH, Davis Aaron I.

Section 16 reporting ended · disclosed 2020-07-21. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	2,107,513	Last balance in matching sequence After 2020-07-21 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2020-07-21 · Conversion · Acquired 1,385,291 · Balance 1,385,291 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Row 3 · 2020-07-21 · Purchase · Acquired 722,222 · Balance 2,107,513 F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Common StockSEC Table I · non-derivative	IndirectSee footnote	23,622	Reported balance After 2020-07-21 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2020-07-21 · Conversion · Acquired 23,622 · Balance 23,622 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2020-07-21 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2020-07-21 · Conversion · Disposed 7,064,136 · Balance 0 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnote	0	Reported balance After 2020-07-21 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2020-07-21 · Conversion · Disposed 120,460 · Balance 0 F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Filing footnotes · ownership attribution and instrument terms

F1: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.

F2: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
January 03, 2022 Filed Jan 5, 2022 21:20 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	SaleCommon Stock	432,903	$47.65	$20,626,182.92	Disclosure SEC source: 0000899243-22-001072 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · Director · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,912,113 F3 · price: Reflects the weighted average sale price. The reporting person effected multiple same-way open market sale transactions on the same day at different prices through a trade order executed by a broker dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The reporting person hereby undertakes to provide upon request by the Securities and Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. The range of prices for such transaction is $47.4904 to $47.8617. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) MVA Investors, LLC ("MVA Investors"), (iv) Aaron I. Davis, and (v) Joseph C. Lewis (collectively, the "Boxer Group"). These securities are owned indirectly by Boxer Management and Joseph C. Lewis, by virtue of their ownership of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
September 17, 2021 Filed Sep 17, 2021 16:38 UTC	Tyra Biosciences, Inc. TYRA · Entity 4680	ConversionSeries B Preferred Stock · Derivative	15,401	$0.00	$0.00	Disclosure SEC source: 0000899243-21-036419 · doc4.xml · derivative · entry 7 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,002 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into shares of the Issuer's common stock at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into shares of the Issuer's common stock at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into shares of the Issuer's common stock at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.direct: These securities are held directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, and indirectly by Mr. Davis who is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
September 17, 2021 Filed Sep 17, 2021 16:38 UTC	Tyra Biosciences, Inc. TYRA · Entity 4680	ConversionSeries B Preferred Stock · Derivative	713,629	$0.00	$0.00	Disclosure SEC source: 0000899243-21-036419 · doc4.xml · derivative · entry 6 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,853,579 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into shares of the Issuer's common stock at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into shares of the Issuer's common stock at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into shares of the Issuer's common stock at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.direct: These securities are held directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Joseph C. Lewis, (iv) MVA Investors, LLC and (v) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
September 17, 2021 Filed Sep 17, 2021 16:38 UTC	Tyra Biosciences, Inc. TYRA · Entity 4680	ConversionSeries A Preferred Stock · Derivative	95,516	$0.00	$0.00	Disclosure SEC source: 0000899243-21-036419 · doc4.xml · derivative · entry 5 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 248,093 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into shares of the Issuer's common stock at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into shares of the Issuer's common stock at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into shares of the Issuer's common stock at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.direct: These securities are held directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, and indirectly by Mr. Davis who is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
September 17, 2021 Filed Sep 17, 2021 16:38 UTC	Tyra Biosciences, Inc. TYRA · Entity 4680	ConversionSeries A Preferred Stock · Derivative	1,480,242	$0.00	$0.00	Disclosure SEC source: 0000899243-21-036419 · doc4.xml · derivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,844,780 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into shares of the Issuer's common stock at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.exercise_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into shares of the Issuer's common stock at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F1 · derivative.expiration_date: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into shares of the Issuer's common stock at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.direct: These securities are held directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Joseph C. Lewis, (iv) MVA Investors, LLC and (v) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
September 17, 2021 Filed Sep 17, 2021 16:38 UTC	Tyra Biosciences, Inc. TYRA · Entity 4680	ConversionCommon Stock	288,095	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-036419 · doc4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 288,095 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into shares of the Issuer's common stock at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F3 · ownership.direct: These securities are held directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, and indirectly by Mr. Davis who is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
September 17, 2021 Filed Sep 17, 2021 16:38 UTC	Tyra Biosciences, Inc. TYRA · Entity 4680	PurchaseCommon Stock	625,000	$16.00	$10,000,000.00	Disclosure SEC source: 0000899243-21-036419 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,323,359 F2 · ownership.direct: These securities are held directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Joseph C. Lewis, (iv) MVA Investors, LLC and (v) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
September 17, 2021 Filed Sep 17, 2021 16:38 UTC	Tyra Biosciences, Inc. TYRA · Entity 4680	ConversionCommon Stock	5,698,359	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-21-036419 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,698,359 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into shares of the Issuer's common stock at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date. F2 · ownership.direct: These securities are held directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Joseph C. Lewis, (iv) MVA Investors, LLC and (v) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
April 27, 2021 Filed Apr 27, 2021 17:09 UTC	Rain Oncology Inc. RAIN · Entity 94695	ConversionNon-Voting Common Stock · Derivative	79,726	$0.00	$0.00	Disclosure SEC source: 0000899243-21-017115 · doc4.xml · derivative · entry 7 Davis Aaron I. · CIK 0001465914 · Director · 10% owner MVA Investors, LLC · CIK 0001468223 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,726 Underlying: Common Stock · 79,726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · derivative.exercise_date: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · derivative.expiration_date: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F3 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, and indirectly by Mr. Davis who is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
April 27, 2021 Filed Apr 27, 2021 17:09 UTC	Rain Oncology Inc. RAIN · Entity 94695	ConversionNon-Voting Common Stock · Derivative	3,022,489	$0.00	$0.00	Disclosure SEC source: 0000899243-21-017115 · doc4.xml · derivative · entry 6 Davis Aaron I. · CIK 0001465914 · Director · 10% owner MVA Investors, LLC · CIK 0001468223 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 3,022,489 Underlying: Common Stock · 3,022,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · derivative.exercise_date: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · derivative.expiration_date: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
April 27, 2021 Filed Apr 27, 2021 17:09 UTC	Rain Oncology Inc. RAIN · Entity 94695	ConversionSeries B Preferred Stock · Derivative	86,097	$0.00	$0.00	Disclosure SEC source: 0000899243-21-017115 · doc4.xml · derivative · entry 5 Davis Aaron I. · CIK 0001465914 · Director · 10% owner MVA Investors, LLC · CIK 0001468223 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Non-Voting Common Stock · 79,726 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · derivative.exercise_date: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · derivative.expiration_date: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F3 · ownership.direct: These securities are owned directly by MVA Investors, which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, and indirectly by Mr. Davis who is a member of and has voting and dispositive power over securities held by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
April 27, 2021 Filed Apr 27, 2021 17:09 UTC	Rain Oncology Inc. RAIN · Entity 94695	ConversionSeries B Preferred Stock · Derivative	3,263,986	$0.00	$0.00	Disclosure SEC source: 0000899243-21-017115 · doc4.xml · derivative · entry 4 Davis Aaron I. · CIK 0001465914 · Director · 10% owner MVA Investors, LLC · CIK 0001468223 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Non-Voting Common Stock · 3,022,489 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · derivative.exercise_date: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F2 · derivative.expiration_date: Each share of Series B Preferred Stock was convertible into Common Stock on a one-for-1.0799 basis at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Series B Preferred Stock had no expiration date. Pursuant to an Exchange Agreement, dated April 17, 2021, the shares of Series B Preferred Stock reported herein were exchanged for shares of Non-Voting Common Stock on a one-for-1.0799 basis immediately prior to the closing of the Issuer's initial public offering without payment or additional consideration. Each share of Non-Voting Common Stock is convertible into one share of Common Stock at any time at the option of the holder without payment or additional consideration, subject to a 9.99% beneficial ownership limitation which may be increased or decreased by the holder upon 61 days' notice to the Issuer. F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
April 27, 2021 Filed Apr 27, 2021 17:09 UTC	Rain Oncology Inc. RAIN · Entity 94695	PurchaseCommon Stock	1,025,000	$17.00	$17,425,000.00	Disclosure SEC source: 0000899243-21-017115 · doc4.xml · nonDerivative · entry 3 Davis Aaron I. · CIK 0001465914 · Director · 10% owner MVA Investors, LLC · CIK 0001468223 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 1,175,000 F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
April 23, 2021 Filed Apr 27, 2021 17:09 UTC	Rain Oncology Inc. RAIN · Entity 94695	PurchaseCommon Stock	125,000	$16.27	$2,033,750.00	Disclosure SEC source: 0000899243-21-017115 · doc4.xml · nonDerivative · entry 2 Davis Aaron I. · CIK 0001465914 · Director · 10% owner MVA Investors, LLC · CIK 0001468223 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 150,000 F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
April 23, 2021 Filed Apr 27, 2021 17:09 UTC	Rain Oncology Inc. RAIN · Entity 94695	PurchaseCommon Stock	25,000	$15.58	$389,500.00	Disclosure SEC source: 0000899243-21-017115 · doc4.xml · nonDerivative · entry 1 Davis Aaron I. · CIK 0001465914 · Director · 10% owner MVA Investors, LLC · CIK 0001468223 · Director · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 25,000 F1 · ownership.nature: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Aaron I. Davis, (iv) MVA Investors, LLC ("MVA Investors"), and (v) Joe Lewis (collectively, the "Boxer Group"), and indirectly by Boxer Management, Mr. Lewis and Mr. Davis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
March 05, 2021 Filed Mar 9, 2021 21:48 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionWarrant (right to purchase) · Derivative	468,639	$13.00 Strike: $0.00	$6,091,838.36	Disclosure SEC source: 0000899243-21-010812 · doc4.xml · derivative · entry 9 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 332,809 Underlying: Common Stock · 468,639 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. F3 · ownership.direct: (Continued from Footnote 2) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
March 05, 2021 Filed Mar 9, 2021 21:48 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionWarrant (right to purchase) · Derivative	128,805	$5.60 Strike: $0.00	$721,179.20	Disclosure SEC source: 0000899243-21-010812 · doc4.xml · derivative · entry 8 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 128,805 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. F3 · ownership.direct: (Continued from Footnote 2) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
March 05, 2021 Filed Mar 9, 2021 21:48 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionWarrant (right to purchase) · Derivative	13,996	$5.60 Strike: $0.00	$78,363.60	Disclosure SEC source: 0000899243-21-010812 · doc4.xml · derivative · entry 7 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,996 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F1 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
March 05, 2021 Filed Mar 9, 2021 21:48 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	363,000	$181.15	$65,757,450.00	Disclosure SEC source: 0000899243-21-010812 · doc4.xml · nonDerivative · entry 6 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,000,000 F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. F3 · ownership.direct: (Continued from Footnote 2) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
March 05, 2021 Filed Mar 9, 2021 21:48 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	4	$181.00	$724.00	Disclosure SEC source: 0000899243-21-010812 · doc4.xml · nonDerivative · entry 5 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,363,000 F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. F3 · ownership.direct: (Continued from Footnote 2) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
March 05, 2021 Filed Mar 9, 2021 21:48 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	597,444	$0.00	$597.44	Disclosure SEC source: 0000899243-21-010812 · doc4.xml · nonDerivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,363,004 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital. F3 · ownership.direct: (Continued from Footnote 2) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
March 05, 2021 Filed Mar 9, 2021 21:48 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	37,000	$181.15	$6,702,550.00	Disclosure SEC source: 0000899243-21-010812 · doc4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,333 F1 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
March 05, 2021 Filed Mar 9, 2021 21:48 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	1	$181.00	$181.00	Disclosure SEC source: 0000899243-21-010812 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,333 F1 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
March 05, 2021 Filed Mar 9, 2021 21:48 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	13,996	$0.00	$14.00	Disclosure SEC source: 0000899243-21-010812 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,334 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
October 30, 2020 Filed Oct 30, 2020 21:54 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionWarrant (right to purchase) · Derivative	37,051	$5.60 Strike: $0.00	$207,448.55	Disclosure SEC source: 0000899243-20-030060 · doc4.xml · derivative · entry 8 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,996 Underlying: Common Stock · 37,051 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F3 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
October 30, 2020 Filed Oct 30, 2020 21:54 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionWarrant (right to purchase) · Derivative	362,952	$5.60 Strike: $0.00	$2,032,168.25	Disclosure SEC source: 0000899243-20-030060 · doc4.xml · derivative · entry 7 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,805 Underlying: Common Stock · 362,952 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.expiration_date: The warrants do not have an expiration date and are not exercisable to the extent that, following exercise of such warrants, the warrant holder and its affiliates would beneficially own more than 19.99% of the issuer's common stock. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital.. Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. F2 · ownership.direct: (Continued from Footnote 1) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
October 30, 2020 Filed Oct 30, 2020 21:54 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Tax withholdingCommon Stock	2	$219.97	$439.94	Disclosure SEC source: 0000899243-20-030060 · doc4.xml · nonDerivative · entry 6 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,765,560 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital.. Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. F2 · ownership.direct: (Continued from Footnote 1) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
October 30, 2020 Filed Oct 30, 2020 21:54 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	362,952	$0.00	$362.95	Disclosure SEC source: 0000899243-20-030060 · doc4.xml · nonDerivative · entry 5 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,765,562 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital.. Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. F2 · ownership.direct: (Continued from Footnote 1) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
October 30, 2020 Filed Oct 30, 2020 21:54 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	362,950	$202.00	$73,315,900.00	Disclosure SEC source: 0000899243-20-030060 · doc4.xml · nonDerivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,404,610 F1 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Braslyn Ltd. ("Braslyn"), (ii) Boxer Capital, LLC ("Boxer Capital") (iii) Boxer Asset Management Inc. ("Boxer Management"), (iv) MVA Investors, LLC ("MVA Investors"), (v) Lockend Five, LLC ("Lockend Five"), (vi) Joe Lewis, (vii) Ivan M. Lieberburg, (viii) Aaron I. Davis, (ix) Shehan B. Dissanayake, and (x) Christopher Fuglesang (collectively, the "Boxer Group), and indirectly by Braslyn, Boxer Management and Messrs. Lewis, Fuglesang, Lieberburg, Dissanayake and Davis, by virtue of their ownership in Boxer Capital.. Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. F2 · ownership.direct: (Continued from Footnote 1) Each of Messrs. Fuglesang, Lieberburg, Dissanayake and Davis is a member of Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
October 30, 2020 Filed Oct 30, 2020 21:54 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Tax withholdingCommon Stock	1	$219.97	$219.97	Disclosure SEC source: 0000899243-20-030060 · doc4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,338 F3 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
October 30, 2020 Filed Oct 30, 2020 21:54 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	Exercise / conversionCommon Stock	37,051	$0.00	$37.05	Disclosure SEC source: 0000899243-20-030060 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 253,339 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
October 30, 2020 Filed Oct 30, 2020 21:54 UTC	Mirati Therapeutics, Inc. MRTX · Entity 94908	SaleCommon Stock	37,050	$202.00	$7,484,100.00	Disclosure SEC source: 0000899243-20-030060 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Davis Aaron I. · CIK 0001465914 · Director · 10% owner LIEBERBURG IVAN M · CIK 0001266427 · 10% owner Dissanayake Shehan Bharatha · CIK 0001663609 · 10% owner Fuglesang Christopher · CIK 0001465835 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,288 F3 · ownership.direct: These securities are owned directly by MVA Investors which may be deemed to be a member of the Boxer Group for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended. Aaron I. Davis is a member of and has voting and dispositive power over securities held by MVA Investors Each member of the Boxer Group other than MVA Investors and Aaron I. Davis disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
September 29, 2020 Filed Sep 29, 2020 16:40 UTC	PMV Pharmaceuticals, Inc. PMVP · Entity 7062	ConversionSeries D Preferred Stock · Derivative	28,129	$0.00	$0.00	Disclosure SEC source: 0001209191-20-052341 · doc4.xml · derivative · entry 9 Boxer Capital, LLC · CIK 0001465837 · Former 10% Owner Boxer Asset Management Inc. · CIK 0001465836 · Former 10% Owner LEWIS JOSEPH · CIK 0001015747 · Former 10% Owner MVA Investors, LLC · CIK 0001468223 · Former 10% Owner Davis Aaron I. · CIK 0001465914 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 28,129 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3 · ownership.nature: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
September 29, 2020 Filed Sep 29, 2020 16:40 UTC	PMV Pharmaceuticals, Inc. PMVP · Entity 7062	ConversionSeries D Preferred Stock · Derivative	732,137	$0.00	$0.00	Disclosure SEC source: 0001209191-20-052341 · doc4.xml · derivative · entry 8 Boxer Capital, LLC · CIK 0001465837 · Former 10% Owner Boxer Asset Management Inc. · CIK 0001465836 · Former 10% Owner LEWIS JOSEPH · CIK 0001015747 · Former 10% Owner MVA Investors, LLC · CIK 0001468223 · Former 10% Owner Davis Aaron I. · CIK 0001465914 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 732,137 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. Read SEC document
September 29, 2020 Filed Sep 29, 2020 16:40 UTC	PMV Pharmaceuticals, Inc. PMVP · Entity 7062	ConversionSeries C Preferred Stock · Derivative	32,708	$0.00	$0.00	Disclosure SEC source: 0001209191-20-052341 · doc4.xml · derivative · entry 7 Boxer Capital, LLC · CIK 0001465837 · Former 10% Owner Boxer Asset Management Inc. · CIK 0001465836 · Former 10% Owner LEWIS JOSEPH · CIK 0001015747 · Former 10% Owner MVA Investors, LLC · CIK 0001468223 · Former 10% Owner Davis Aaron I. · CIK 0001465914 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 32,708 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3 · ownership.nature: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
September 29, 2020 Filed Sep 29, 2020 16:40 UTC	PMV Pharmaceuticals, Inc. PMVP · Entity 7062	ConversionSeries C Preferred Stock · Derivative	586,099	$0.00	$0.00	Disclosure SEC source: 0001209191-20-052341 · doc4.xml · derivative · entry 6 Boxer Capital, LLC · CIK 0001465837 · Former 10% Owner Boxer Asset Management Inc. · CIK 0001465836 · Former 10% Owner LEWIS JOSEPH · CIK 0001015747 · Former 10% Owner MVA Investors, LLC · CIK 0001468223 · Former 10% Owner Davis Aaron I. · CIK 0001465914 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 586,099 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.exercise_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F2 · derivative.expiration_date: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. Read SEC document
September 29, 2020 Filed Sep 29, 2020 16:40 UTC	PMV Pharmaceuticals, Inc. PMVP · Entity 7062	ConversionCommon Stock	28,129	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-052341 · doc4.xml · nonDerivative · entry 5 Boxer Capital, LLC · CIK 0001465837 · Former 10% Owner Boxer Asset Management Inc. · CIK 0001465836 · Former 10% Owner LEWIS JOSEPH · CIK 0001015747 · Former 10% Owner MVA Investors, LLC · CIK 0001468223 · Former 10% Owner Davis Aaron I. · CIK 0001465914 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 60,837 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3 · ownership.nature: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
September 29, 2020 Filed Sep 29, 2020 16:40 UTC	PMV Pharmaceuticals, Inc. PMVP · Entity 7062	ConversionCommon Stock	32,708	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-052341 · doc4.xml · nonDerivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · Former 10% Owner Boxer Asset Management Inc. · CIK 0001465836 · Former 10% Owner LEWIS JOSEPH · CIK 0001015747 · Former 10% Owner MVA Investors, LLC · CIK 0001468223 · Former 10% Owner Davis Aaron I. · CIK 0001465914 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 32,708 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F3 · ownership.nature: The shares are held of record by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
September 29, 2020 Filed Sep 29, 2020 16:40 UTC	PMV Pharmaceuticals, Inc. PMVP · Entity 7062	ConversionCommon Stock	732,137	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-052341 · doc4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · Former 10% Owner Boxer Asset Management Inc. · CIK 0001465836 · Former 10% Owner LEWIS JOSEPH · CIK 0001015747 · Former 10% Owner MVA Investors, LLC · CIK 0001468223 · Former 10% Owner Davis Aaron I. · CIK 0001465914 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,268,236 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. Read SEC document
September 29, 2020 Filed Sep 29, 2020 16:40 UTC	PMV Pharmaceuticals, Inc. PMVP · Entity 7062	ConversionCommon Stock	586,099	Not disclosed	Not disclosed	Disclosure SEC source: 0001209191-20-052341 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · Former 10% Owner Boxer Asset Management Inc. · CIK 0001465836 · Former 10% Owner LEWIS JOSEPH · CIK 0001015747 · Former 10% Owner MVA Investors, LLC · CIK 0001468223 · Former 10% Owner Davis Aaron I. · CIK 0001465914 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,536,099 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The shares of each of the Series C Preferred Stock and Series D Preferred Stock shall automatically convert into shares of Common Stock on a one to one basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and have no expiration date. F1 · ownership.direct: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. Read SEC document
September 25, 2020 Filed Sep 29, 2020 16:40 UTC	PMV Pharmaceuticals, Inc. PMVP · Entity 7062	PurchaseCommon Stock	950,000	$18.00	$17,100,000.00	Disclosure SEC source: 0001209191-20-052341 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · Former 10% Owner Boxer Asset Management Inc. · CIK 0001465836 · Former 10% Owner LEWIS JOSEPH · CIK 0001015747 · Former 10% Owner MVA Investors, LLC · CIK 0001468223 · Former 10% Owner Davis Aaron I. · CIK 0001465914 · Former 10% Owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 950,000 F1 · ownership.direct: The shares are held of record by Boxer Capital, LLC ("Boxer Capital") which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, LLC ("MVA Investors") (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:38 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	ConversionSeries B-2 Preferred Stock · Derivative	158,687	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-020687 · doc4.xml · derivative · entry 6 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 48,691 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F1 · shares: Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. F2 · shares: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F2 · price: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F2 · derivative.exercise_date: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F2 · derivative.expiration_date: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F1 · derivative.underlying_shares: Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. F2 · derivative.underlying_shares: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F4 · ownership.direct: These securities are owned directly by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:38 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	ConversionSeries B-2 Preferred Stock · Derivative	9,593,086	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-020687 · doc4.xml · derivative · entry 5 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,943,568 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F1 · shares: Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. F2 · shares: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F2 · price: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F2 · derivative.exercise_date: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F2 · derivative.expiration_date: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F1 · derivative.underlying_shares: Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. F2 · derivative.underlying_shares: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F3 · ownership.direct: These securities are owned directly by Boxer Capital, which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:38 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	PurchaseCommon Stock	23,552	$19.00	$447,488.00	Disclosure SEC source: 0000899243-20-020687 · doc4.xml · nonDerivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,243 F6 · shares: On July 28, 2020, MVA Investors purchased 23,552 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. F6 · ownership.direct: On July 28, 2020, MVA Investors purchased 23,552 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:38 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	PurchaseCommon Stock	1,401,448	$19.00	$26,627,512.00	Disclosure SEC source: 0000899243-20-020687 · doc4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,345,016 F5 · shares: On July 28, 2020, Boxer Capital purchased 1,401,448 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. F5 · ownership.direct: On July 28, 2020, Boxer Capital purchased 1,401,448 shares of Common Stock of the Issuer at a price of $19.00 per share pursuant to an underwritten public offering. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:38 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	ConversionCommon Stock	48,691	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-020687 · doc4.xml · nonDerivative · entry 2 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,691 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. F2 · shares: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F2 · price: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F4 · ownership.direct: These securities are owned directly by MVA Investors. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
July 28, 2020 Filed Jul 29, 2020 21:38 UTC	iTeos Therapeutics, Inc. ITOS · Entity 75965	ConversionCommon Stock	2,943,568	Not disclosed	Not disclosed	Disclosure SEC source: 0000899243-20-020687 · doc4.xml · nonDerivative · entry 1 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,943,568 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Each share of Series B-2 Convertible Preferred stock is convertible at any time, at the Reporting Person's election, into Common Stock, based on the then-applicable conversion rate and has no expiration date. F2 · shares: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F2 · price: The shares of Series B-2 Convertible Preferred stock held by Boxer Capital, LLC ("Boxer Capital") will convert automatically into 2,943,568 shares of Common Stock upon the closing of the Issuer's initial public offering. The shares of Series B-2 Convertible Preferred stock held by MVA Investors, LLC ("MVA Investors") will convert automatically into 48,691 shares of Common Stock upon the closing of the Issuer's initial public offering. These amounts reflect a 1-for-3.3115 reverse stock split which became effective on July 20, 2020. F3 · ownership.direct: These securities are owned directly by Boxer Capital, which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc., (iii) MVA Investors, (iv) Aaron I. Davis, and (v) Joe Lewis (collectively, the "Boxer Group"). Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it does not have a pecuniary interest therein. Read SEC document
July 21, 2020 Filed Jul 21, 2020 19:49 UTC	Pandion Therapeutics, Inc. PAND · Entity 11788	ConversionSeries B Preferred Stock · Derivative	120,460	$0.00	$0.00	Disclosure SEC source: 0000899243-20-019894 · doc4.xml · derivative · entry 5 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 23,622 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F3 · ownership.nature: These securities are owned directly and solely by MVA Investors, which has sole voting and dispositive power with respect to these securities. Each member of the Boxer Group other than MVA Investors disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
July 21, 2020 Filed Jul 21, 2020 19:49 UTC	Pandion Therapeutics, Inc. PAND · Entity 11788	ConversionSeries B Preferred Stock · Derivative	7,064,136	$0.00	$0.00	Disclosure SEC source: 0000899243-20-019894 · doc4.xml · derivative · entry 4 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,385,291 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.exercise_date: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F1 · derivative.expiration_date: The Series B Preferred Stock converted into Common Stock on a 5.0994-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date. F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document
July 21, 2020 Filed Jul 21, 2020 19:49 UTC	Pandion Therapeutics, Inc. PAND · Entity 11788	PurchaseCommon Stock	722,222	$18.00	$12,999,996.00	Disclosure SEC source: 0000899243-20-019894 · doc4.xml · nonDerivative · entry 3 Boxer Capital, LLC · CIK 0001465837 · 10% owner Boxer Asset Management Inc. · CIK 0001465836 · 10% owner Braslyn Ltd. · CIK 0001642355 · 10% owner LEWIS JOSEPH · CIK 0001015747 · 10% owner Davis Aaron I. · CIK 0001465914 · 10% owner MVA Investors, LLC · CIK 0001468223 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,107,513 F2 · ownership.direct: These securities are owned directly by Boxer Capital, LLC ("Boxer Capital"), which may be deemed to be a member of a "group" for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, consisting of (i) Boxer Capital, (ii) Boxer Asset Management Inc. ("Boxer Management"), (iii) Braslyn Ltd. ("Braslyn"), (iv) Joseph C. Lewis, (v) MVA Investors, LLC ("MVA Investors") and (vi) Aaron I. Davis (collectively, the "Boxer Group"), and indirectly by Boxer Management and Joseph C. Lewis by virtue of their ownership in Boxer Capital. Each member of the Boxer Group other than Boxer Capital disclaims beneficial ownership of these securities to the extent it or he does not have a pecuniary interest therein. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.